G-1 (CAS 881639-98-1): Selective GPR30 Agonist in Immune and Cardiac Research

Introduction

Rapid advances in estrogen signaling research have uncovered novel mechanisms beyond the classical nuclear estrogen receptors (ERα and ERβ). At the forefront of these discoveries is G-1 (CAS 881639-98-1), a highly selective G protein-coupled estrogen receptor 30 (GPR30/GPER1) agonist. G-1 enables targeted interrogation of non-genomic estrogen pathways, offering a unique vantage point for dissecting immune modulation, cardiac remodeling, and cancer cell migration. Unlike prior reviews focused on translational strategy or workflow troubleshooting, this article critically examines the mechanistic underpinnings of G-1 action—bridging molecular pharmacology with practical assay design—while contextualizing its value against alternative approaches and recent literature.

Mechanism of Action of G-1: Selective GPR30 Agonist

G-1 is a small-molecule ligand (molecular weight 412.28, C₂₁H₁₈BrNO₃) engineered for nanomolar affinity and extraordinary selectivity for GPR30/GPER1 (K_i ≈ 11 nM), with negligible activity at classical ERα/ERβ even at micromolar concentrations. Upon binding to GPR30, which predominantly localizes to the endoplasmic reticulum, G-1 initiates a cascade of intracellular events. Notably, it elevates intracellular calcium (EC₅₀ = 2 nM) and triggers PI3K-dependent nuclear accumulation of phosphatidylinositol (3,4,5)-trisphosphate (PIP3), modulating downstream kinases and transcriptional machinery. These rapid, non-genomic effects distinguish G-1 from ligands acting on nuclear estrogen receptors, providing a tool to isolate GPR30-specific signaling in complex biological systems.

Reference Insight Extraction: Decoding GPR30's Role in Immune Homeostasis

The most compelling recent advance comes from a pivotal study (Peng Wang et al., 2021) dissecting estrogen signaling in hemorrhagic shock. Here, researchers demonstrated that activation of GPR30 by either estradiol or G-1 normalized proliferation and cytokine production of splenic CD4+ T lymphocytes after traumatic blood loss. This immune restoration was mechanistically linked to inhibition of endoplasmic reticulum (ER) stress—a pathway not engaged by ERβ agonists, but critically dependent on both ERα and GPR30. Importantly, the study employed genetic and pharmacological controls, including GPR30 antagonists and ERS inducers, to pinpoint the necessity of GPR30 in mediating these non-classical, rapid immunomodulatory effects. For practical assay design, this work underscores the value of G-1 for distinguishing GPR30-driven responses from classical ER-mediated effects, especially in models where immune, cardiovascular, or inflammatory endpoints are influenced by estrogen signaling.

Comparative Analysis: G-1 Versus Alternative Estrogen Pathway Probes

Traditional studies of estrogen function have relied on natural hormones (estradiol) or subtype-selective nuclear ER agonists (e.g., PPT for ERα, DPN for ERβ). However, these ligands often lack specificity for non-genomic pathways. G-1’s selectivity is transformative: it enables researchers to parse rapid GPR30-mediated effects without confounding activation of ERα or ERβ. For example, the reference study found that only G-1 and ERα agonists (not ERβ agonists) could restore CD4+ T cell function following hemorrhagic shock, and that GPR30 antagonists abrogated this benefit—an effect not observed with classical ER blockade alone. This specificity is vital for studies targeting GPR30 activation in cardiovascular research or modeling inhibition of breast cancer cell migration where overlapping receptor expression could otherwise confound interpretation.

Advanced Applications in Immunology and Cardiovascular Research

GPR30 Activation in Cardiovascular and Immune Models

G-1’s utility extends beyond basic receptor pharmacology. In vivo, chronic administration of G-1 (120 μg/kg for 14 days) to ovariectomized female rats with heart failure reduced brain natriuretic peptide (BNP) levels, attenuated cardiac fibrosis, and improved contractile function via normalization of β1-adrenergic receptor and upregulation of β2-adrenergic receptor expression, as detailed in the product information. These findings position G-1 as a robust model reagent for studies of cardiac fibrosis attenuation and heart failure, offering a selective means to probe GPR30’s cardioprotective actions.

In parallel, G-1’s capacity to modulate immune cells is highlighted in the hemorrhagic shock study. The restoration of CD4+ T lymphocyte proliferation and cytokine production was linked to reduced ER stress, a mechanism supported by the observation that ERS inducers negated G-1’s protective effects. Thus, G-1 enables precise modeling of estrogenic immune regulation, particularly in trauma, sepsis, or inflammatory models where non-genomic signaling is suspected to play a role.

Oncology: Inhibition of Breast Cancer Cell Migration

In vitro, G-1 demonstrates potent inhibition of breast cancer cell migration, with IC₅₀ values of 0.7 nM (SKBr3) and 1.6 nM (MCF7) in cell lines co-expressing estrogen receptors. This selectivity is critical in breast cancer research, where classical ERs often confound interpretation of rapid estrogenic effects. For researchers seeking to isolate GPR30 selective ligand activity in oncogenic signaling, G-1 offers a unique profile: minimal off-target action, high potency, and robust discrimination of GPR30-driven pathways.

Protocol Parameters

• Stock Solution Preparation: Dissolve G-1 at ≥41.2 mg/mL in DMSO. Solutions at >10 mM are recommended for experimental use. Apply gentle warming and ultrasonic treatment to optimize solubility.
• Storage: Store stock solutions at -20°C and use promptly to prevent degradation.
• Shipping: Ship on blue ice for small molecule integrity.
• In Vivo Dosing: For cardiac and immune models, chronic administration at 120 μg/kg/day for 14 days has demonstrated efficacy in rat models of heart failure and immune dysfunction (see product details).
• In Vitro Dosing: For breast cancer cell migration assays, nanomolar concentrations (0.7–1.6 nM) are effective in SKBr3 and MCF7 lines.
• Controls: Include ERα and ERβ agonists/antagonists (e.g., PPT, DPN, ICI 182,780) to distinguish receptor subtype effects as demonstrated in the reference study.
• Assay Readouts: For immune assays, measure CD4+ T cell proliferation and cytokine production after hemorrhagic or inflammatory challenge; for cardiac studies, assess BNP, fibrosis, and contractile parameters.

Why This Article Offers a Distinct Perspective

While previous reviews such as "G-1 (CAS 881639-98-1): Redefining Translational Research..." have surveyed the mechanistic landscape and competitive positioning of G-1, and practical guides like "Leveraging G-1 (CAS 881639-98-1)" have focused on workflow optimization, this article uniquely bridges mechanistic biochemistry with real-world assay protocol decisions. It draws directly from recent breakthrough studies to illuminate how G-1 can dissect the immunomodulatory roles of GPR30 in trauma and cardiac models—an angle not deeply explored in earlier content. Furthermore, while "G-1: Selective GPR30 Agonist for Cardiovascular and Cancer..." provides a broad overview of application strategies, we critically analyze the intersection of ER stress modulation, immune restoration, and receptor selectivity to inform both experimental design and broader translational implications.

Why this cross-domain matters, maturity, and limitations

The cross-talk between immune restoration and cardiac remodeling via GPR30 activation has far-reaching implications. For example, attenuation of ER stress in immune cells may not only benefit trauma-induced immunosuppression but also modulate inflammation-driven cardiac fibrosis. However, while animal models and cell lines provide robust mechanistic insight, translation to human pathophysiology remains an area for future validation. Thus, G-1 is best positioned as a research reagent for mechanistic studies, with clinical extrapolation requiring careful consideration of species differences and receptor expression patterns.

Conclusion and Future Outlook

G-1 (CAS 881639-98-1) represents a paradigm shift in the study of non-classical estrogen signaling. Its high selectivity and nanomolar potency enable researchers to dissect GPR30-driven pathways in immune, cardiovascular, and oncological contexts with unprecedented clarity. The ability to modulate ER stress and restore immune function, as elucidated in the seminal reference study, positions G-1 as an invaluable tool for advancing our understanding of estrogenic regulation of health and disease. As research continues to bridge molecular mechanisms with translational outcomes, reagents like G-1—supplied by APExBIO—will remain central to innovation in cardio-immunology and cancer biology.